Data shows that a single payer system has the potential to reduce health care expenditures despite criticism that it would raise costs.

A JAMA Oncology study shows that hospital list pricing posted online, which is referred to as a chargemaster, is often significantly different than what a patient is billed.

In a recent white paper, CVS Health outlined four strategies that could improve patient access and care, as well as lead to significant payer cost reduction for gene therapies.

In rural areas, high-deductible health plans threaten patients' financial heath, but they are not the only ones; hospitals are also experiencing related fiscal struggles.

“New treatments that delay disease progression in patients with hematologic cancer could have a significant impact on the economic burden of hematologic malignancies,” researchers wrote.

Nonmyeloablative conditioning was associated with lower reimbursement and improved overall survival 1 year after allogeneic hematopoietic cell transplantation in a group of older adults with acute myeloid leukemia, according to study findings.

Continuing the effort to increase access for patients, Eli Lilly will be offering two new half-priced versions of its Humalog Junior KwikPen and Humalog Mix75/25 insulin products.

After receiving FDA approval as the first treatment for patients with a rare form of stomach cancer, Blueprint Medicine Corp's Ayvakit was priced at over $30,000 per month. 

The Camden Coalition of Healthcare Providers program—which was designed to reduce spending and improve care quality for high utilization patients—was found to have little effect on readmission rates, according to recent clinical trial data.

Researchers compared health care spending data for the US and Canada and found that the US spends four times more per person in administrative costs than Canada in its single-payer system.